Openbookopenbook
Equity
RXRX
+0.0 · +0.00%
USD · NASDAQ

Recursion Pharmaceuticals Inc(RXRX) Stock Analysis | Healthcare

USD --+0.00%
Reward50Moderate
Risk49Moderate
75%Data
Revenue down 60% YoY
Profitless Growth
Market Cap:1.79Bn
ⓘ
Reward Rating
50
Moderate
Reward Assessment
75% data coverage
Bottom 50% of stocksView factors
ⓘ
Risk Rating
49
Moderate
Risk Assessment
5 metrics flaggedView details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on RXRX to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
New listing — limited trading history
Fundamental and analyst data are available for RXRX, but momentum and volatility metrics will develop as more trading history accumulates (0 trading sessions so far).
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

Analyst Target

Analyst consensus price target: $7.22.

What is Recursion Pharmaceuticals Inc?

, a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom.

RXRX · Verdict

Moderate reward · moderate risk

RXRX stands out on balance sheet and growth, but watch the cash flow signal.

Based on 88% data coverage

RXRX · Verdict

What’s working & what to watch

Strengths 2

  • Balance sheet76/100

    Current ratio 5.50

  • Growth69/100

    Rev +23.5% CAGR · earnings +39.1%

Watchouts 2

  • Cash flow6/100

    -507% free-cash-flow margin

  • Profitability9/100

    -863% net margin · -57% ROE

Model-based scoring. For information only — not financial advice.

What is Recursion Pharmaceuticals Inc?

, a clinical-stage biotechnology company, engages in the decoding biology and chemistry by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery in the United States and the United Kingdom. The company develops REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-617, which is in Phase 1/2 clinical trial to treat advanced solid tumors; REC-1245, which is in Phase 1/2 clinical trial to treat biomarker-enriched solid tumors and lymphoma; REC-3565 that is in Phase 1/2 for the treatment of relapsed or refractory B-cell malignancies; and REC-4539, a reversible, CNS penetrant, orally bioavailable, and potential best-in-class inhibitor of LSD1 for the treatment of solid tumors and hematology oncology. The company is listed on the NASDAQ in USA, operating in the Healthcare sector, with a market capitalisation of 1.79B.

Financial Highlights

Investment Breakdown

Growth
Moderate growth momentum — positive trajectory without breakout acceleration.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (50)

The scoring profile indicates limited reward potential at this time, with growth and valuation offering the most support. Risk indicators are moderate, consistent with typical market exposure.

For informational purposes only. Not financial advice.

Similar stocks to compare

A short list of Biotechnology names that are close enough in size to make side-by-side comparison useful.

ONTTFSmall Cap / 1.8B market cap
Oxford Nanopore Technologies Limited
Compare
NTLASmall Cap / 1.8B market cap
Intellia Therapeutics Inc
Compare
LKFTSmall Cap / 1.8B market cap
Lakefront Biotherapeutics NV
Compare
Company Information
SectorHealthcare
IndustryBiotechnology
Market Cap1.79B
P/E RatioN/A
Dividend YieldN/A
Beta1.054
Insider Activity
12M windowBearish
Shares soldShares bought
0-3months
0
0
3-6months
366,254 shares
$215k
0
6-9months
6819,212 shares
$3.5M
0
9-12months
0
0
openbook

Stock research for UK and US investors. Make smarter decisions, faster.

Questions? Email us at contact@openbookanalytics.com

© 2026 Openbook Analytics Ltd · Company No. SC843579 · Registered in Scotland

256-bit encryption GDPR compliant UK data centres

Openbook Analytics Ltd (Company No. SC843579) is registered in Scotland. Registered office: Strathclyde Inspire Hub, University of Strathclyde, Graham Hills Building (Level 6), 50 Richmond Street, Glasgow, G1 1XP. Openbook Analytics is not authorised or regulated by the Financial Conduct Authority (FCA). The content on this platform is provided for general informational and educational purposes only and does not constitute financial advice, investment advice, trading advice, or any other form of advice. You should not treat any content on this platform as a recommendation to buy, sell, or hold any financial instrument. Past performance is not a reliable indicator of future results. The value of investments and the income from them can go down as well as up, and you may get back less than you invest. User-generated content, including community posts and commentary, reflects the personal opinions of individual users, is not verified for accuracy, and does not represent the views of Openbook Analytics Ltd. You should always conduct your own research or consult a qualified, FCA-regulated financial adviser before making investment decisions. Data displayed on this platform may be delayed or inaccurate and is provided "as is" without warranty. Openbook Analytics Ltd accepts no liability for any loss arising from reliance on the information provided.